Riskpilot← Back to searchSign inGet full accessNAMENA APOTEK AS
ASActiveOrg 926018256Essendrops gate 9, 0368 OsloRetail sale of pharmaceutical products · NACE 4773Est. 202015 employees
Revenue 2025
NOK 31,6M
+57% vs 2024
EBITDA margin
4.4%
+265% vs 2024
Equity ratio
15.4%
Financial strength
Net profit 2025
NOK 845K
+5376% vs 2024
| Revenue | NOK 31,6M | +57% |
| EBITDA | NOK 1,4M | +265% |
| Net profit | NOK 845K | +5376% |
| Total assets | NOK 4,5M | +13% |
| Equity | NOK 697K | +7% |
| Employees | 15 | — |
Legal name
NAMENA APOTEK AS
Org number
926018256
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
23. november 2020
Share capital
NOK 600 000
Employees
15 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Company purpose
Å eie og drive apotek og alt hva hermed står i forbindelse.
Address
Essendrops gate 9, 0368 Oslo
Phone
+4721934900
Email
webmaster@lynxapotek.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 4 644 | 7 034 | 9 742 | 20 088 | 31 597 |
| Staff expenses | −1 721 | −2 215 | −2 407 | −2 396 | −3 279 |
| EBITDA | −276 | 902 | 1 120 | 385 | 1 405 |
| Depreciation & amort. | −203 | −232 | −233 | −233 | −235 |
| EBIT | −479 | 670 | 888 | 152 | 1 170 |
| Net financials | −110 | −119 | −140 | −131 | −87 |
| Profit before tax | −590 | 551 | 748 | 21 | 1 083 |
| Tax | −129 | 122 | 165 | 5 | 238 |
| Net profit | −460 | 429 | 584 | 15 | 845 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 3 524 | 4 427 | 5 053 | 3 992 | 4 530 |
| Equity | 74 | 503 | 1 086 | 652 | 697 |
| Long-term debt | 2 467 | 2 067 | 1 683 | 1 272 | 0 |
| Short-term debt | 983 | 1 858 | 2 283 | 2 068 | 2 967 |
| Total debt | 3 450 | 3 925 | 3 966 | 3 341 | 3 834 |
EBITDA margin
4.4%
This company
15.8%
Market median
-72% vs market
20212025
Equity ratio
15.4%
This company
38.2%
Market median
-60% vs market
20212025
Return on equity
121.3%
This company
18.4%
Market median
+559% vs market
20212025
Net profit margin
2.7%
This company
8.1%
Market median
-67% vs market
20212025
Asset turnover
6.97×
This company
1.12×
Market median
+522% vs market
20212025
Debt / equity
5.50×
This company
0.62×
Market median
-787% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
BB Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2020 | |
| Board of Directors | 2020 | |
| Board of Directors | 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 60% | 60% | 2024 | |
| Company | 30% | 30% | 2024 | |
| Company | 10% | 10% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Rajkovic Holding As
NAMENA APOTEK AS Board members of NAMENA APOTEK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bjarne Brudeli | Chief Executive Officer | 0 companies |
| Alexander Berntsen Rajkovic | Chairman | 0 companies |
| Fredrik Giil Liisberg | Board of Directors | 0 companies |
| Torleiv Idsøe Holst | Board of Directors | 0 companies |